Ann Arbor, MI – AgelessRx, a leader in telehealth-driven longevity solutions, is proud to announce significant advancements in its clinical research initiatives aimed at extending human healthspan. Following the successful completion of the PEARL (Participatory Evaluation of Aging with Rapamycin for Longevity) trial, the company is now expanding participant recruitment for ongoing and upcoming longevity clinical trials to further explore innovative therapies targeting the aging process.
PEARL Trial: A Milestone in Longevity Research
The PEARL trial stands as the largest and longest decentralized, double-blind, placebo-controlled study assessing the safety and efficacy of low-dose rapamycin in generally healthy adults aged 50 to 85. Conducted over 48 weeks, the trial demonstrated that intermittent, low-dose rapamycin is safe and well-tolerated, with participants experiencing measurable improvements in key health metrics.
Notably, the study found significant gains in lean muscle mass and reductions in self-reported pain among women receiving 10 mg of rapamycin weekly. Additionally, participants taking 5 mg weekly reported enhancements in emotional well-being and general health. These findings suggest that rapamycin could play a critical role in preventive medicine, offering an evidence-based strategy to potentially optimize health and delay age-related decline.
Expanding Research Horizons
Building on the success of the PEARL trial, AgelessRx is actively recruiting participants for new studies aimed at further investigating rapamycin's potential benefits. In collaboration with Simmaron Research, the company is conducting a study titled “Low-Dose Rapamycin in ME/CFS, Long-COVID, and Other Infection-Associated Chronic Conditions.” This research seeks to explore rapamycin's efficacy in addressing symptoms associated with these conditions, potentially offering new therapeutic avenues for affected individuals.
AgelessRx continues to leverage its telehealth platform to facilitate decentralized clinical trials, ensuring broader accessibility and the opportunity to participate in longevity research. This approach not only accelerates data collection but also reflects real-world usage patterns, enhancing the applicability of research findings.
Join the Journey to Better Health
Individuals interested in contributing to the advancement of longevity science are encouraged to participate in AgelessRx's ongoing clinical trials. Eligible participants will have the opportunity to be part of groundbreaking research that aims to redefine aging and promote healthier, longer lives.
For more information on current studies and eligibility criteria, please visit AgelessRx Research.
About AgelessRx
AgelessRx is at the forefront of the longevity revolution, offering clinically validated cutting-edge solutions and preventive treatments aimed at extending life expectancy and enhancing quality of life. AgelessRx also continues to advance the field of longevity science by conducting ongoing research and clinical trials. Through its online platform, AgelessRx provides easy access to innovative healthcare services, with an emphasis on customer satisfaction, affordability, and the pursuit of a future where extended healthspan is a reality for everyone.
Email: press@agelessrx.com
Media Contact
Name
AgelessRx
Contact name
Anar Isman
Contact phone
650-503-9990
Contact address
2370 E Stadium Blvd #2049
City
Ann Arbor
State
MI
Zip
48104
Country
United States
Url
https://www.agelessrx.com/
